STING1 and plasma cell myeloma: On these bases, we could start to imagine a chemo‐free treatment history for myeloma patients, where immunotherapy (IMiDs, bispecific agents, CAR‐T)57 as well as drugs able to elicit a strong autologous immune response (immunogenic cell death inducers, such as bortezomib or innovative target drugs such as STING agonists, hypomethylating agents or cancer vaccines)52 will be combined to achieve long and sustained responses with minimal toxicities.